BioWorld Asia

Dec. 22, 2004

Pharmos Crashes On Data From Phase III Brain Study

Once high on Pharmos Corp.'s cannabinoid-receptor drug for brain injury, investors came down hard following news that the compound failed in a pivotal Phase III trial.(BioWorld International) Read More

CAT Wins Court Battle Over Humira; Abbott Logs Appeal

Gene Therapy Boosts Hope For Blood Disease Therapies

Eyeing Cancer Drugs, Aphton Acquiring Igeneon For $81M

Europe Tackles Distinction In Similar Biotech Orphan Drugs

Phytopharm Product, Not Good For Pharma, Aimed At Foods

'Right Time': Bavarian Nordic To Form Cancer Vaccine Unit In U.S.

NicOx Taking Lead CINOD Into Phase III Osteoarthritis Program

Metabolic Jumps, Slides On Trial Data, Analyst Criticism

Santhera Raises Additional EUR7M In Second Closing Of Financing

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 24, 2026.

Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

BioWorld Science

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...

4D Nucleome opens new wave of gene regulation research, discovery

BioWorld

After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...

Transcripta Bio raises funding to advance neuro pipeline

BioWorld Science

Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...

Daybu readthrough in EU? Zevra’s NPC bid flounders

BioWorld

Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...